Pro: The routine use of aprotinin during pediatric cardiac surgery is a benefit

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 13, Issue 6, 1999, Pages 782-784

  D'Errico, Celia C ^a   Munro, Hamish M ^b   Bove, Edward L ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Aprotinin; Bleeding; Coagulation; Pediatric cardiac surgery

Indexed keywords

APROTININ;

CARDIOPULMONARY BYPASS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; HEMOSTASIS; HUMAN; INFLAMMATION; MEDIASTINITIS; PEDIATRIC SURGERY; PRIORITY JOURNAL; REVIEW;

EID: 0033406627     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(99)90136-2     Document Type: Article

References (28)

1. Groom RC, Akl BF, Albus R, Lefrak EA: Pediatric cardiopulmonary bypass: A review of current practice. Int Anesthesiol Clin 34:141-163, 1996
2. Urban AE, Popov-Cenic S, Noe G, Kulzer R: Aprotinin in open-heart surgery of infants and children using the heart-lung machine. Clin Ther 6:425-433, 1984
3. Herynkopf F, Lucchese F, Pereira E, et al: Aprotinin in children undergoing correction of congenital heart defects: A double-blind pilot study. J Thorac Cardiovasc Surg 108:517-521, 1994
4. Hazan E, Pasaoglu I, Demircin M, Bozer AY: The effect of aprotinin (Trasylol) on postoperative bleeding in cyanotic congenital heart disease. Turk J Pediatr 33:99-109, 1991
5. Penkoske PA, Entwistle LM, Marchak BE, et al: Aprotinin in children undergoing repair of congenital heart defects. Ann Thorac Surg 60:529-532, 1995
6. Jaquiss RDB, Huddleston CB, Spray TL: Use of aprotinin in pediatric lung transplantation. J Heart Lung Transplant 14:302-307, 1995
7. D'Errico CC, Shayevitz JR, Martindale SJ, et al: The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 83:1193-1199, 1996
8. Dietrich W, Mossinger H, Spannagl M, et al: Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 105:712-720, 1993
9. Davies MJ, Allen A, Kort H, et al: Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg 63:497-503, 1997
10. Primack C, Walenga JM, Koza MJ, et al: Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg 61:1188-1193, 1996
11. Shinfield A, Zippel D, Lavee J, et al: Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate. Ann Thorac Surg 59:872-876, 1995
12. Wachtfogel YT, Hack CE, Nuijens JH, et al: Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol Heart Circ Physiol 268:H1352-H1357, 1995
13. Nagaoka H, Yamada T, Hatano R, et al: Clinical significance of bradykinin liberation during cardiopulmonary bypass and its prevention by a kallikrein inhibitor. Jpn J Surg 5:222-233, 1975
14. Twedell JS, Berger S, Frommelt PC, et al: Aprotinin improves outcome of single-ventricle palliation. Ann Thorac Surg 62:1329-1336, 1996
15. Hill GE, Alonso A, Spurzem JR, et al: Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-1662, 1995
16. Gurevitch J, Barak J, Hochhauser E, et al: Aprotinin improves myocardial recovery after ischemia and reperfusion. J Thorac Cardiovasc Surg 108:109-118, 1994
17. Wendel HP, Heller W, Michel J, et al: Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 109:1164-1172, 1995
18. Boldt J, Knothe C, Zickmann B, et al: Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations: Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 105:705-711, 1993
19. Elliott MJ, Allen A: Aprotinin in paediatric cardiac surgery. Perfusion 5:73-76, 1990
20. Carrel TP, Schwanda M, Vogt PR, et al: Aprotinin in pediatric cardiac operations: A benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 66:153-158, 1998
21. Clar A, Larson DF: Hemofiltration: Determinants of drug loss and concentration. J Extracorpor Technol 27:158-163, 1995
22. Miller BE, Tosone SR, Tam VK, et al: Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 66:535-541, 1998
23. MacClure PD, Izsak J: The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology 40:604-608, 1974
24. Reynolds LM, Nicolson SC, Jobes DR, et al: Desmopressin does not decrease bleeding after cardiac operation in young children. J Thorac Cardiovasc Surg 106:954-958, 1993
25. Seear MD, Wesworth LD, Rogers PC, et al: The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 98:217-219, 1998
26. Rocha E, Hidalgo F, Lorens R, et al: Cardiopulmonary bypass: Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 90:921-927, 1994
27. Eberle B, Mayer E, Hafner G, et al: High-dose epsilon-aminocaproic acid versus aprotinin: Antifibrinolytic efficacy in first-time coronary operations. Ann Thorac Surg 65:667-673, 1998
28. Dietrich W, Spath P, Ebell A, Richter JA: Prevalence of anaphylactic reactions to aprotinin: Analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 113:194-201, 1997